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The Editorial on the Research Topic
Gene Targeting in Neuroscience: Entering the Future
Many methods are available for the manipulation of brain function and behavior. From
pharmacological tools through electrophysiological techniques to neuroanatomical procedures,
an arsenal of approaches has been successfully utilized to answer the question of how the brain
works and what may be behind its dysfunction in human disorders. Why do many scientists prefer
to use genetics then? There may be two principally different reasons for this choice: one relates
to evolution, the other to practical or mechanistic points. Ultimately, all behavioral features of
an organism, and thus all functional aspects of its brain, must pass the test of natural selection.
Natural selection operates at the level of genes. In other words, albeit often complex and difficult
to disentangle, the effects of genes on brain function and behavior is not questionable. The
second reason is more practical, and concerns how efficiently a biologist can answer mechanistic
questions. The cause of human CNS disorders is often multifaceted, and is usually expected to
involve numerous unknown environmental factors. Simply put, the number of such environmental
factors could be staggering, whereas the number of genes one can manipulate is only about 25,000.
Identifying a gene is also much simpler than identifying environmental agents possibly involved
in brain dysfunction. A good example for this reasoning is the discovery of the involvement of
Amyloid Precursor Protein (APP) misprocessing in Alzheimer’s Disease. Only <5% of Alzheimer
cases are familial, i.e., heritable, yet it was the discovery, for example, of APP mutations and the
mutations in APP processing enzymes that propelled the understanding of the disease forward.
Another mechanistic reason why genetic manipulation is often preferred to other methods is the
specificity of the former. Modern recombinant DNA methods allow one to precisely silence a
single gene, or change its expression in a brain region specific manner, or even modulate neuronal
function in particular circuits and at particular time points. This level of control, temporal and
spatial resolution, as well as target specificity are often not achievable with methods other than
genetics. The current special topic will present numerous such genetic techniques, the first, and
perhaps the most famous of which being homologous recombination-based gene targeting in
embryonic stem cells.
The double selection scheme that allowed efficient identification of homologous recombination-
based replacements of endogenous genes with a targeting vector in embryonic stem cells has
revolutionized reverse genetics. The method, developed by Mario Capecchi and his colleagues
in the mid-80s, which became known as gene targeting or the knock out technology, has since
been widely used in studies investigating the function of genes in practically every sub-discipline
of biology. This special topic presents a collection of papers that focus on how gene targeting has
been utilized in neurobiology, i.e., in the analysis of the biological mechanisms of brain function and
behavior. It reviews classical (first generation) knock outmethods and second generation (inducible
and cell type restricted gene expression and targeting) techniques, including the CRE-recombinase
system, the evolution of the technology as well as the evolution of its use (Tsien; Gerlai).
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The latter papers describe what we have learned over the past
three decades about the utility and the limitations of gene
targeting in brain research, and what the potential future of this
technology may be. The special topic also extends the question
of how gene targeting is employed for the discovery of gene
function to how it may be used to generate animal models of
human brain disorders (Leung and Jia). In the past decade,
novel genome engineering tools have also been developed. These
new methods now compete with the true and tried ES cell
based gene-targeting technique. For example, the Transcription
activator-like effector nuclease (TALEN) system now allows one
to custom design restriction endonuclease-like enzymes that will
cut specifically at the desired nucleotide sequence (Lee et al.).
Similarly, the Clustered regularly-interspaced short palindromic
repeats (CRISPR) andCRISPR associated protein 9 (Cas9) system
now also enables the researcher to create double stranded cuts
at pre-specified nucleotide sequences of choice (Walters et al.).
Importantly, both the TALEN and the CRISPR/Cas9 system can
be employed in species other than the mouse or the rat, the
two laboratory model organisms to which ES cell based gene-
targeting methods of the past were restricted. Last, the special
topic also reviews the Designer Receptors Exclusively Activated
by Designer Drugs (DREADD) technology (Whissell et al.).
Although not a gene targeting method per se, DREADD is a
recombinant DNA manipulation-based approach that combines
genetics with pharmacology and allows one to specifically target
particular neuronal populations and conduct a high temporal
resolution analysis of their function.
As the saying goes, “clearly we are living exciting times”
(unconfirmed source, but believed to originate from a Chinese
curse). The investigator now has an array ofmodern recombinant
DNA-based tools with which he or she can manipulate
brain function and/or behavior. The number of such tools is
continually growing, and the context in which they are employed
is increasing in breadth. This special topic only captures a
fraction of these methods and the different ways they may be
employed. Nevertheless, it attempts to paint an objective picture
discussing the pros and cons of these tools. As such, it may
be a useful read for the novice neurobehavioral geneticist and
the expert neurobiologist alike. It may be of value to scientists
of other fields of biology as well who wish to employ these
techniques for purposes other than the investigation of the brain.
Last, we feel the papers may be useful for both instructors
and students who are interested in the rapidly evolving field of
neurobehavioral genetics and modern behavioral neuroscience.
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